Semaglutide — research catalogue reference
November 8, 2026
Retatrutide and tirzepatide act on overlapping hormone pathways. Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors; retatrutide is a triple agonist targeting GLP-1, GIP and glucagon receptors. These mechanisms distinguish the peptide compounds, but receptor activity alone doesn’t establish comparative clinical outcomes.
Mechanism provides another point of comparison. Semaglutide is a GLP-1 receptor agonist; tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds glucagon-receptor activity, making it a triple agonist. Researchers are examining whether this broader metabolic action affects body weight and other outcomes, including in people with overweight or obesity.
Aussie Peptides: Retatrutide
For laboratory work, retain the compound identity, lot details and Certificate of Analysis with the relevant study records. Contact Aussie Peptides to discuss its research-grade compounds and batch documentation.
Aussie Peptides offers research-grade Retatrutide, Semaglutide and BPC-157. If your next step is sourcing compounds for laboratory work, use the product and batch documentation to support your study records. For information about the available research compounds, contact Aussie Peptides.
Tirzepatide is a peptide that activates two hormone receptors, GLP-1 and GIP. Researchers study these pathways in relation to glucose regulation and body weight. In Australia, tirzepatide was registered as Mounjaro as of September 2026. Its identity as a dual-receptor agonist describes its mechanism; it doesn’t make trial outcomes interchangeable across different conditions or study designs.
The main distinctions are receptor activity, evidence base and research status. Semaglutide acts on one receptor pathway, tirzepatide on two, and retatrutide on three. Some compounds and outcomes have been directly compared, but separate trials cannot establish a head-to-head difference. For a specific study, define the outcome first, then compare compounds using aligned populations and measurement methods.
These compounds act as receptor agonists, meaning they activate selected hormone receptors. The resulting biological signals are studied for their effects on appetite, digestion, glucose regulation and body weight. Receptor activity identifies the pathway under investigation, not the size of a clinical effect. Researchers assess each outcome separately rather than assuming that a broader receptor profile produces a greater effect.
How do semaglutide, tirzepatide, and retatrutide work, and which receptors do they target?
Semaglutide targets GLP-1 receptors. Tirzepatide targets GLP-1 and GIP receptors, while retatrutide targets GLP-1, GIP and glucagon receptors. These targets distinguish their pharmacological mechanisms. In a laboratory or trial comparison, record the receptor profile separately from outcomes such as glucose or body-weight changes; those measures require their own evidence and cannot be inferred from receptor targets alone.
Materials in this catalogue are offered for in-vitro laboratory research only, not human or veterinary use. This reference does not provide dosing, preparation, storage or treatment instructions.
Check the listing identity
Read the compound name, labelled amount and any blend composition on the current product listing. An amount per vial is not a dose or a preparation protocol. Current prices and availability belong to the catalogue, not an older article.
Check a lot document, where published
A report is shown only if one has been published for that lot. Compare its identifiers with the listing and vial label. A missing report is not evidence of testing or quality.
Consult the appropriate source
For handling, consult the supplier safety data sheet and your institution's standard operating procedures. For regulatory questions, consult official TGA guidance; a research-use label does not determine legal status.
Research catalogue · Lot documents · Official guidance · Shipping details and carrier estimates · Contact